News

Opioid use declines among elderly, but still ‘substantial’

Opioid use among older Medicare beneficiaries dropped during a recent 4-year period, but a “substantial” number of these individuals were considered chronic and heavy opioid users, researchers wrote.The findings were presented during the American Public Health Association Annual Meeting and Expo.“The opioid epidemic is in a critical state in our country, even during the COVID‐19…

News

Minimal monitoring program achieves SVR in hepatitis C

In a minimal monitoring – or “Minmon” – study, patients given a full regimen for hepatitis C virus and then remotely monitored achieved 95% sustained virologic response, according to a presenter at The Liver Meeting Digital Experience.“Though this trial was designed before the COVID pandemic, I like to think of it as COVID-proof or COVID-friendly…

News

Aspirin reduces risk for HCC in chronic hepatitis B

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma, according to a presenter at The Liver Meeting Digital Experience.“Cirrhosis had a significant effect on the association between use of aspirin and the risk of HCC development,” Heejoon Jang, MD, from the department of internal medicine and Liver Research…

News

AI program uses vocal biomarkers to diagnose COVID-19

An artificial intelligence voice analysis tool can help diagnose COVID-19 in asymptomatic patients, according to its manufacturer, Vocalis Health.The technology — called VocalisCheck — works by comparing a person’s voice sample to a COVID-19-positive voice composite. VocalisCheck assesses their risk level of testing positive for COVID-19 and whether they require further testing.According to the company,…

News

COVID, MIS-C show evidence of liver injury, require long-term monitoring

Children with COVID-19 and multisystem inflammatory syndrome had varied outcomes and liver injuries but all should keep long-term liver monitoring to ensure return to normal levels, per a researcher at The Liver Meeting Digital Experience.“Patients with either MIS-C or COVID-10 had liver injury. In both cohorts, patients with liver injury were statistically more likely to…

News

VIDEO: Odevixibat well tolerated in progressive familial intrahepatic cholestasis

In this exclusive video, Richard Thompson, MD, PhD, discussed results from two abstracts presented at The Liver Meeting Digital Experience on using odevixibat in progressive familial intrahepatic cholestasis.Thompson, professor of molecular hepatology at King’s College London, reported that odevixibat was well tolerated in the phase 3 extension study. Results showed significant reductions in serum bile…

News

Combination therapies impact NAFLD more than singular therapy

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.“In this randomized, 24-week, phase 2a trial, both semaglutide and combination regimens including semaglutide, firsocostat and/or cilofexor were well tolerated in NASH patients with mild-to-moderate fibrosis,”…